Pyxis Oncology (PYXS) Change in Account Payables (2020 - 2025)
Pyxis Oncology (PYXS) reported Change in Account Payables of $1.1 million for Q4 2025, up 11390.0% year-over-year from N/an in Q4 2024, and up 228.2% quarter-over-quarter from $344000.0 in Q3 2025.
Pyxis Oncology (PYXS) Change in Account Payables (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of Change in Account Payables data on file, last reported at $1.1 million in Q4 2025.
- Change in Account Payables for Q4 2025 came in at $1.1 million, up 11390.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.0 million (up 402.17% YoY), and the FY2025 annual result was $6.0 million, up 402.17% from the prior year.
- Change in Account Payables grew to $1.1 million in Q4 2025 per PYXS's latest filing, from $344000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $6.6 million in Q2 2025 and troughed at -$9.9 million in Q1 2022.
- A 5-year average of $1700.0 and a median of -$228500.0 in 2021 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables tumbled 2113.87% in 2022, then jumped 11390.0% in 2025.
- A 5-year view of Change in Account Payables shows it stood at $4.0 million in 2021, then plunged by 146.74% to -$1.9 million in 2022, then jumped by 118.57% to $350000.0 in 2023, then slumped by 102.86% to -$10000.0 in 2024, then jumped by 11390.0% to $1.1 million in 2025.
- Business Quant data shows PYXS's Change in Account Payables at $1.1 million in Q4 2025, $344000.0 in Q3 2025, and $6.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 344,000.00 |
| Sep 30, 2025 | 344,000.00 |
| Jun 30, 2025 | 6.57 Mn |
| Jun 30, 2025 | 6.57 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Dec 31, 2024 | -10,000.00 |
| Dec 31, 2024 | -10,000.00 |
| Sep 30, 2024 | -602,000.00 |
| Sep 30, 2024 | -602,000.00 |
| Jun 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Mar 31, 2024 | -1.37 Mn |
| Mar 31, 2024 | -1.37 Mn |
| Dec 31, 2023 | 350,000.00 |
| Dec 31, 2023 | 350,000.00 |
| Sep 30, 2023 | -1.54 Mn |
| Sep 30, 2023 | -1.54 Mn |